Cory berkland.

A new pH-sensitive triblock copolymer, polyethylene glycol-block-poly(2-dimethylaminoethyl methacrylate)-block-poly(2-diisopropylaminoethyl methacrylate) (PEG-PDMA-PDPA), was synthesized via atom transfer radical polymerization (ATRP).The potential of this polymer for siRNA delivery was assessed. This triblock copolymer formed nanocapsules with high siRNA encapsulation efficiency that ...Cory Berkland Chronic iron overload is a serious condition that develops as a consequence of long-term accumulation of iron, eventually overwhelming iron storage systems and causing oxidative ... View Cory Berkland's record in Saint Louis, MO including current phone number, address, relatives, background check report, and property record with Whitepages. • -- ...Mar 1, 2011 · 1. Introduction. Injectable scaffolds have received attention due to their potential for avoiding the invasive surgery typically required for tissue implantation. 1 From a clinical perspective, the use of injectable materials is an attractive alternative to surgery as it reduces the risk of infection, scar formation, patient discomfort and the cost of treatment. 2 Injectable scaffolds may be ... 1. Introduction. Injectable scaffolds have received attention due to their potential for avoiding the invasive surgery typically required for tissue implantation. 1 From a clinical perspective, the use of injectable materials is an attractive alternative to surgery as it reduces the risk of infection, scar formation, patient discomfort and the cost of treatment. …

Min Huang 1 and Cory Berkland 1, 2, * Author ... Peek LJ, Coop T, Berkland C. Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth ...Cory Berkland, PhD. CEO, BOND BIOSCIENCES. Saint Louis, Missouri, United States. Dr. Berkland serves as the Chairman of the Board, President, Chief Executive Officer …

AU - Berkland, Cory. N1 - Funding Information: We gratefully acknowledge support from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (R56 AI091996), the National Institute of General Medical Sciences (T32 GM008359), the Kansas IDeA Network of Biomedical Research Excellence, the PhRMA Foundation ...Apr 6, 2017 · Patent number: 10398649. Abstract: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles. Type: Grant. Filed: October 16, 2017. Date of Patent: September 3, 2019. Assignee: Orbis Biosciences, Inc. Inventors: Cory Berkland, Milind Singh.

Cory Berkland holds the Solon E. Summerfield Distinguished Professorship in the Department of Pharmaceutical Chemistry and in the Department of Chemical Engineering at The University of Kansas. He received MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois in Urbana-Champaign and a BS degree in Chemical Engineering from Iowa State ...BERKLAND CORY, WANG QUN. Author information. Affiliations. All authors. 1. UNIV KANSAS Patent: Publ. of Application with search report - European Patent Office Application: EP20080848334 on 06 Nov 2008 Publication: 06 Nov 2008 PAT: EP2217295 . Patent. Share this article ...Cory Berkland Laird Forrest Michael Hageman Jeff Krise Sue Lunte Russ Middaugh Christian Schöneich Teruna Siahaan John Stobaugh Thomas Tolbert David Volkin Michael Wang Undergraduate Research Program ...Cory Berkland, PhD. CEO, BOND BIOSCIENCES. Saint Louis, Missouri, United States. Dr. Berkland serves as the Chairman of the Board, President, Chief Executive Officer …Europe PMC is an archive of life sciences journal literature.

Cory Berkland · Aug 9 '20. Our lab at The University of Kansas has partnered with Sean and the Foothold Labs team. I have been impressed by the sensitivity and accuracy of the NanoRev system. Sean and his colleagues have been reliable and results-oriented collaborators.

Supang Khondee, Tatyana Yakovleva, Cory Berkland. First published: 04 August 2010. https://doi.org/10.1002/app.32460. Citations: 2. Read the full text. PDF. …

Jim Berkland. James O. Berkland (July 31, 1930 - July 22, 2016) was an American geologist [1] who controversially claimed to be able to predict earthquakes, including the 1989 Loma Prieta earthquake and 1994 Northridge Earthquake [2] and who popularized the idea that some people are earthquake sensitive. He was profiled in a popular 2006 book ...Cory Berkland. Chemical & Petroleum Engineering, 1530 West 15th Street, University of Kansas, Lawrence, Kansas 66045-7609. Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence, Kansas 66045-7609. Search for more papers by this authorCory Berkland, Chief Executive Officer of Bond, commented that "we are highly encouraged by these results, which demonstrate the mechanism and clinical activity of BBI-001 after just a single dose.Barlas Büyüktimkin, 1 Qun Wang, 2 Paul Kiptoo, 1 John M. Stewart, 1 Cory Berkland, 1, 2 and Teruna J. Siahaan 1, * Barlas Büyüktimkin 1 Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KSAbstract. Lung surfactant is crucial for optimal pulmonary function throughout life. An absence or deficiency of surfactant can affect the surfactant pool leading to respiratory distress. Even if the coupling between surfactant dysfunction and the underlying disease is not always well understood, using exogenous surfactants as replacement is ...Abstract: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles. Type: Grant. Filed: August 16, 2019. Date of Patent: February 14, 2023. Assignee: ADARE PHARMACEUTICALS USA, INC. Inventors: Cory Berkland, Milind Singh.

Cory Berkland. 2007, Journal of Pharmaceutical Sciences. Novel macromolecular therapeutics such as peptides, proteins, and DNA are advancing rapidly toward the clinic. Because of typically low oral bioavailability, macromolecule delivery requires invasive methods such as frequently repeated injections. Parenteral depots including biodegradable ...Cory Berkland: Resources, Writing - review & editing. Michael J. Hageman: Writing - review & editing, Project administration, Supervision, Resources. Declaration of Competing Interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in ...Charles Allen Thomas Professor of Chemistry, Chair and Professor of Chemistry. John . HeemstraCory Berkland. Professor. Biomedical Engineering. [email protected]. Google Scholar. Education. PhD, University of Illinois, …Cory Berkland, CEO [email protected]. Release Summary. Phase Ia/b will assess the safety of BBI-001 and test the ability of BBI-001 to prevent iron uptake from food. Contacts.Cory Berkland Laird Forrest Michael Hageman Jeff Krise Sue Lunte Russ Middaugh Christian Schöneich Teruna Siahaan John Stobaugh Thomas Tolbert David Volkin Michael Wang Undergraduate Research Program ...

11‏/02‏/2023 ... Curt Berkland passed away on February 11, 2023 in Emmetsburg, Iowa. Funeral Home Services for Curt are being provided by Martin-Mattice ...Dr. Cory Berkland Solon E. Summerfield Distinguished Professor School of Engineering, School of Pharmacy Chemical and Petroleum Engineering, Pharmaceutical Chemistry RESEARCH INTERESTS Antigen-specific immunotherapies, sequestering cells to combat autoimmunity, autoimmunity and tolerance reintroduction, targeted drug delivery, and gene delivery.

The Axioforce Team Cory Berkland Professor in the Department of Pharmaceutical Chemistry and in the Department of Chemical Engineering at The University of Kansas.Dr. Cory J. Berkland, Committee Chair February 3rd, 2015_____ Date approved . iii ABSTRACT Self-assembling and shear-responsive biomaterials possess favorable rheological and viscoelastic properties to be injectable and facilitate minimally invasive surgery. The current thesis workChuda Chittasupho, Teruna J Siahaan, Charlotte M Vines, Cory Berkland. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Therapeutic Delivery 2011, 2 (7) , 873-889.Pressnall MM, Huayamares SG, Berkland CJ. Immunostimulant Complexed with Polylysine Limits Transport and Maintains Immune Cell Activation. Journal of Pharmaceutical Sciences. PMID 32565351 DOI: 10.1016/j.xphs.2020.06.009 : 0.56: 2020: Griffin JD, Song JY, Sestak JO, DeKosky BJ, Berkland CJ. Linking autoantigen properties to mechanisms of immunity.Cory Berkland. Professor. Biomedical Engineering. [email protected]. Google Scholar. Education. PhD, University of Illinois, …Jun 6, 2017 · INTRODUCTION. Autoimmune diseases such as multiple sclerosis (MS) are typified by a breakdown of healthy immune regulation and subsequent misrecognition of self for non-self. 1–2 The autoimmune breakdown in MS is largely propagated by autoreactive T and/or B cell clonal expansion and attack against myelin sheath autoantigens, leading to demyelination and neurodegeneration. 3–6 Activation ... Cory Berkland View For the in vitro release experiment, 50 µl of UM-3003 adsorbed alhydrogel formulation was mixed with 500 µl of adjuvant-free human plasma in a closed glass vial at 37 °C and ...Eventbrite - Corporate Faith presents Corporate Faith - 2023 Business Speakers Series - Cory Berkland - Monday, August 14, 2023 at Undivided Experience Center, Chesterfield, MO. Find event and ticket information. Assembling executives who also have a tremendous faith. We have a discussion on how the two are intertwined and create sustainable ...Dr. Cory Berkland. Solon E. Summerfield Distinguished Professor. School of Engineering, School of Pharmacy. Chemical and Petroleum Engineering, Pharmaceutical Chemistry. …pH-sensitive triblock copolymers for efficient siRNA encapsulation and delivery†. Check for updates. Jian Qiana and Cory Berkland*ab. Author affiliations.

BERKLAND CORY, MOHAMMADI ZAHRA. Author information. Affiliations. All authors. 1. UNIV KANSAS Patent: Publ.of the Int.Appl. with Int.search report - World Intellectual Property Organization Application: WO2011US26872 on 02 Mar 2011 Publication: 02 Mar 2011 PAT: WO2011109521 ...

Feb 14, 2022 · The company’s lead candidate, BBI-001, is an iron chelator for the treatment of hereditary hemochromatosis. Bond joins the St. Louis ecosystem after licensing technology originally developed at the University of Kansas. Bond was founded by St. Louisan and serial entrepreneur Cory Berkland, PhD.

Brittany L Hartwell 1 , Chad J Pickens 2 , Martin Leon 3 , Cory Berkland 1 2 4 Affiliations 1 Bioengineering Graduate Program, University of Kansas 1520 West 15th Street, Lawrence, Kansas 66045, United States. 2 Department of Pharmaceutical Chemistry, University of Kansas 2095 Constant Avenue ...The main apparatus (Fig. 1A), which provides fabrication of monodisperse microparticles, is based on passing a solution containing the sphere material, and any drug to be encapsulated, through a small nozzle or other orifice (20 μm to a few millimeters in diameter) to form a smooth, cylindrical jet.To controllably break the jet into droplets, the nozzle is vibrated by a piezoelectric ...Cory Berkland; Cory Berkland. CEO at Bond Biosciences. Join to edit. About. Dr. Berkland serves as the Chairman of the Board, President, Chief Executive Officer (CEO), and Co-Founder of Bond Biosciences. He is taking a partial leave as Distinguished Professor at The University of Kansas to advance the business and to ensure the development and ...Cory's current address is 1300 Coconino Rd, Ames, IA. We know that one company — Mmc Photography, LLC — is registered at this address. We know that Julie M Anderson, Hyungjoo Choi, and 374 other persons also lived at this address, perhaps within a different time frame.Records show that Cory also lived at 802 Dickinson Ave, Ames, IA 50014.Cory Berkland: Resources, Writing - review & editing. Michael J. Hageman: Writing - review & editing, Project administration, Supervision, Resources. Declaration of Competing Interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work …Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors . Pharmaceutical Research . 2003 Jul 1;20(7):1055-1062. doi: 10.1023/A:1024466407849Brittany L. Hartwell, Aaron Smalter Hall, David Swafford, Bradley P. Sullivan, Aaron Garza, Joshua O. Sestak, Laura Northrup, and Cory Berkland. Molecular Dynamics of Multivalent Soluble Antigen Arrays Support a Two-Signal Co-delivery Mechanism in the Treatment of Experimental Autoimmune Encephalomyelitis.Cory J. Berkland [email protected] Department of Chemical and Petroleum Engineering, University of Kansas, 1530 West 15th Street, Lawrence, KS, 66045 USA. Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, KS, 66047 USA. E-mail: [email protected] Search for more papers by this authorThe long-term objective of this application is to deliver a unique biomaterial that can easily be molded into place by a surgeon, and will resorb as it induces rapid tissue regeneration. Toward this o...Burkholderia pseudomallei, the etiological agent responsible for melioidosis, exhibits a great public health toll in its endemic regions. The elevation of B. pseudomallei to a Tier I select agent underscores the urgent need for effective therapeutics and preventatives. The current treatment regimen for melioidosis is suboptimal, requiring an intensive phase of intravenous antibiotic followed ...May 5, 2019 · Hartwell BL; Pickens CJ; Leon M; Berkland C, Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis. Biomacromolecules 2017, 18 (6), 1893–1907. [PMC free article] [Google Scholar]

Loop is the open research network that increases the discoverability and impact of researchers and their work. Loop enables you to stay up-to-date with the latest discoveries and news, connect with researchers and form new collaborations.Cory Berkland. The Berkland Lab investigates pharmaceuticals and biomaterials. They aim to understand the transport of pharmaceuticals as a function of physical and chemical properties. Biomaterials are also investigated for applications in regenerative medicine. Faculty Profile. Berkland Research Lab.Jan 25, 2022 · Cory Berkland, CEO [email protected] Release Summary Bond’s clinical lead, BBI-001, is designed to rapidly and selectively bind dietary iron to reduce iron absorption in patients with iron overload. Instagram:https://instagram. tvfool tv signal locatorkobe bryant ku footballlowes metal bracketwhen does spring 2024 start Khia Preston Director Of Operations at The UPS Store - #3263, 2473, 3354, 3723, 1152, 3443, 0754 how does workers comp work in kansasi blp What We Do. Our lab works at the interface of medicine and engineering with an emphasis on precisely controlling the physical and chemical properties of particles and biomaterials. The lab environment fosters multidisciplinary interaction between graduate and undergraduate researchers from the departments of Chemical and Petroleum Engineering ... kansas state football game time Three decades of promise have culminated in the development of gene therapies that can be applied to a broad range of human diseases. After a brief history, we provide an overview of gene therapy types and delivery methods, gene editing technologies, regulatory affairs, clinical trials, approved pro … AU - Berkland, Cory. AU - Kim, Kyekyoon. AU - Pack, Daniel W. PY - 2003/7/1. Y1 - 2003/7/1. N2 - Purpose. Although the rate of drug release from poly(D,L-lactide-co-glycolide) (PLG) microspheres is often modulated by changing fabrication conditions or materials, the specific factors directly controlling the release profiles are often unclear.